Navigation Links
Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
Date:9/25/2007

HORSHAM, Pa., Sept. 25 /PRNewswire/ -- Findings from an international, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial evaluating ustekinumab (CNTO 1275) in the treatment of moderate to severe plaque psoriasis will be presented for the first time at the 21st meeting of the World Congress of Dermatology, which takes place from Sept. 30 to Oct. 5, 2007 in Buenos Aires, Argentina.

The presentation, entitled CNTO 1275 (anti-IL-12/23p40) Treatment of Psoriasis: Phase 3 Trial Results will take place on Wednesday, Oct. 3, 2007 from 11 a.m. to 1 p.m. local time (GMT +3:00; 10:00 a.m. to 12:00 p.m. EDT), Room A, La Rural Convention Center, Buenos Aires, Argentina.

These first reported findings will be the subject of a live press briefing and webcast, which will be broadcast from the World Congress of Dermatology on Wednesday, Oct. 3 at 2 p.m. EDT. Media and analysts are invited to register at http://www.CNTO1275WCD.com and listen live on Oct. 3 as investigators from the trial will review and discuss the data.

About Ustekinumab

Ustekinumab is a new, fully-human monoclonal antibody in Phase 3 development by Centocor, Inc. for the treatment of moderate to severe plaque psoriasis and is being investigated as an infrequently-administered subcutaneous injection. Ustekinumab is a novel biologic therapy that targets interleukin 12 (IL-12) and interleukin 23 (IL-23), naturally occurring proteins that are important in normalizing the immune system and that are also believed to play a role in immune-mediated inflammatory diseases.

Centocor discovered ustekinumab and has exclusive marketing rights to the product in the United States. Janssen-Cilag companies will market ustekinumab in all countries outside of the United States.

About Psoriasis

Psoriasis is a chronic, immune-mediated disease that results from inflammation in the skin and overproduction of skin ce
'/>"/>

SOURCE Centocor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in Phase III Pivotal Trial Compared to Neostigmine
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July, 29  2014 ISPE—the International Society ... John Bournas as President and CEO, ... to leave the Society last fall.  Mr. Bournas ... in the healthcare association industry as well as ... a clear vision for the expansion of its ...
(Date:7/29/2014)... , July 29, 2014  Roche (SIX: RO, ... Association for Clinical Chemistry (AACC) 2014 Clinical Lab Expo ... on the unique ways Roche is partnering with customers ... "Our customers tell us every day that they,re looking ... they deliver in their labs and offices," said ...
(Date:7/29/2014)... July 29, 2014 Research and Markets ... Respiratory Devices Market 2014-2018" report to their offering. ... A respiratory device is a medical device used to ... difficulty in breathing and cannot achieve adequate oxygen levels ... cystic fibrosis, asthma, COPD, and ARDS require the need ...
Breaking Medicine Technology:ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 2Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 3Roche focuses on partnering with customers to redefine the value of the laboratory at the AACC 2014 Clinical Lab Expo 4Global Respiratory Devices Market 2014-2018 2
... April 28, 2011 ResMed Inc. (NYSE: RMD ... ended March 31, 2011.  Revenue for the quarter ended March ... 12% increase on a constant currency basis) over the quarter ... 2011, income from operations was $64.0 million and net income ...
... Financial Highlights ($ in millions, except ... , $109.5 , 28.8% increaseTotal Net Product Revenue , ... , 24.7% increaseAldurazyme BioMarin Net Product Revenue* , $18.7 ... increaseFirdapse Net Product Revenue , $3.1 , $0.1GAAP Net ...
Cached Medicine Technology:ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 2ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 3ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 5ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 6BioMarin Announces First Quarter 2011 Financial Results 2BioMarin Announces First Quarter 2011 Financial Results 3BioMarin Announces First Quarter 2011 Financial Results 4BioMarin Announces First Quarter 2011 Financial Results 5BioMarin Announces First Quarter 2011 Financial Results 6BioMarin Announces First Quarter 2011 Financial Results 7BioMarin Announces First Quarter 2011 Financial Results 8BioMarin Announces First Quarter 2011 Financial Results 9BioMarin Announces First Quarter 2011 Financial Results 10BioMarin Announces First Quarter 2011 Financial Results 11
(Date:7/29/2014)... (GSA) the nation,s largest interdisciplinary organization devoted ... E. Lckenhoff, PhD, of Cornell University as the 2014 ... Foundation Award in Behavioral and Social Gerontology. , This ... in behavioral and social gerontology. Individuals who have received ... The award is given by GSA in conjunction with ...
(Date:7/29/2014)... July 29, 2014 The report ... Cosmetics), Type (Rotary, Volumetric, Aseptic, Net Weight), Process ... Geography - Global Trend & Forecast to 2019”, ... into food, beverage, pharmaceutical, and cosmetic segments with ... each of these segments, in terms of value. ...
(Date:7/29/2014)... Calif. (PRWEB) July 29, 2014 July ... drug abuse directly at the source? That’s the big ... an innovative prescription drug abuse risk program developed by ... hundreds of applicants worldwide to be part of ... 10-12 in San Francisco, CA. The Hive is a ...
(Date:7/29/2014)... -- With the increasing use of electronic medical ... growing demand for a computerized version of the ... States. In a new study, researchers from the ... Institute report that substantial work lies ahead to ... guidelines into computerized prompts for physicians, but the ...
(Date:7/29/2014)... 29, 2014 The Los Angeles ... recently participated in a community program that helps homeless ... volunteers partnered with the San Fernando Valley Rescue Mission ... , The San Fernando Valley Rescue Mission offers emergency ... mission's Family Emergency Shelter provides housing and basic needs ...
Breaking Medicine News(10 mins):Health News:Löckenhoff earns GSA's 2014 Baltes Foundation Award 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 2Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 3Health News:Filling Equipment Market worth $8 Billion by 2019 - Report by MarketsandMarkets 4Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 2Health News:SafeUseNow Selected to Showcase at TEDMED Hive 2014 3Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3Health News:The Discovery House Employees Volunteer at Local Rescue Mission 2Health News:The Discovery House Employees Volunteer at Local Rescue Mission 3
... off in Northwestern PA , , HARRISBURG, Pa., June ... the harms of tobacco use on their unborn babies, the ... Control Program are launching a new smoking cessation campaign to ... that region of the state. , , "More ...
... as QM Certified Scoring Partner , , LINCOLN, ... Innoventz, a clinical research organization (CRO) for medical device ... QM Certified Scoring Partner. QualityMetric developed the QM Certified ... many in the life sciences industry -- the accuracy ...
... San Diego, CA, June 22, 2009 Because of ... and children with asthma is recommended by the Advisory ... call for annual influenza vaccination of at least 60% ... for Disease Control and Prevention (CDC) investigators have determined ...
... Mass., June 22 Joseph F. Finn, Jr., C.P.A. ... on developing GCS-100 for treatment of three blood-borne cancers: ... large B cell lymphoma ("DLBCL"). In clinical studies, ... CLL and in combination with existing therapy in MM. ...
... Martha Lucas, Ph.D., L.Ac., Denver-based acupuncturist and practitioner of Traditional ... to Cosmetic Acupuncture for Anti-aging. The announcement is ... tells the history of vanity and what women have been ... Now there,s a healthy, safe option - Cosmetic Acupuncture. ...
... The ... for their own health. Celebrity Diagnosis is an innovative approach to personalized medicine that ... unique feature of Celebrity Diagnosis is the casebook, a convenient and portable information packet ... ...
Cached Medicine News:Health News:State Launches New Campaign to Help Pregnant Smokers Go Tobacco-Free 2Health News:Innoventz Certified to Score Both the SF-36v2 and SF-12v2 Health Surveys 2Health News:Innoventz Certified to Score Both the SF-36v2 and SF-12v2 Health Surveys 3Health News:Adults with asthma not getting their flu shots 2Health News:Prospect Therapeutics Inc.'s GCS-100 Has Focused on Developing Treatment for Three Blood-Borne Cancers 2Health News:Denver-Based Acupuncturist, Dr. Martha Lucas, Releases New Book: 'Vanity Calamity: Your Guide to Cosmetic Acupuncture for Anti-aging' 2Health News:CelebrityDiagnosis.com Presents Famous Patients As Medical Lessons 2Health News:CelebrityDiagnosis.com Presents Famous Patients As Medical Lessons 3
Ideal for abdominal and flank procedures....
Male Abdominal Supporter...
Zippered Abdominal Girdle...
CDIs 2nd Stage Abdominoplasty Girdle - a feminine, easy pull-on version of the 8000 series...
Medicine Products: